Solid–Liquid Phase Equilibrium and Mixing Properties of Cloxacillin Benzathine in Pure and Mixed Solvents

Experimental solubility data of cloxacillin benzathine in pure solvents and binary solvent mixtures from 278.15 to 313.15 K were measured using a multiple reactor setup. The measured data in pure solvents were correlated by the van’t Hoff equation, modified Apelblat equation, <i>λh</i> equation, Wilson model, and NRTL model, and the Wilson model showed the best agreement. Thus, the activity coefficients of cloxacillin benzathine as well as the mixing Gibbs free energies, enthalpies, and entropies of the solutions were predicted with the correlation of experimental data based on the Wilson model. Some other properties were also estimated, including the infinite-dilution activity coefficients and excess enthalpies in pure solvents. The solubility data in binary solvent mixtures as a function of solvent composition were correlated by the Wilson model. The negative values of the calculated partial molar Gibbs free energies indicated the variation trend of the solubility

Additional file 3: of Genome-wide association study identified ATP6V1H locus influencing cerebrospinal fluid BACE activity

The correlation between age and CSF BACE activity. (TIF 2436 kb

Additional file 1: of Genome-wide association study identified ATP6V1H locus influencing cerebrospinal fluid BACE activity

The MDS plot of samples. (TIF 8989 kb

Additional file 1 of Multi-omics analysis reveals overactive inflammation and dysregulated metabolism in severe community-acquired pneumonia patients

Supplementary Material 1: Table S1.1. Additional characteristics of NS-CAP patients, Related to Figure 1. Table S1.2. Additional characteristics of S-CAP patients, Related to Figure 1. Table S1.3. Additional characteristics of DCs, Related to Figure 1. Table S1.4. Additional characteristics of HCs, Related to Figure

La Toque blanche : organe professionnel hebdomadaire des chefs de cuisine de France et de l'étranger

02 mars 19281928/03/02 (N157)

Kinetics of the expression of the JEV DNA vaccine immunogen.

<p>Mice (n = 5) were immunized with plasmids without booster. JEV prM-E protein expression was measured by ELISA in the undiluted sera collected at pre-inoculation and 1, 3, 5, 7, 14 and 21 days post-inoculation. Data are expressed as the mean values of OD with a SD.</p

Dynamics of the Ab response of JEV DNA-immunized mice were detected by ELISA.

<p>Booster administrations were performed at week 3 and 6. Pre- and post-immunization serum samples (n = 10, 1∶800) were collected and then Ab titers were determined. The bar graph shows the mean ± standard deviation (SD) values for optical density (OD) of the group vaccinated with plasmids: gray-colored bars, mice co-inoculated with 50 µg pCAG-JME and 50 µg pCAG-GM; black bars, mice inoculated with a mixture of 50 µg pCAG-JME and 50 µg pCAGGSP7; hollow bars, mice inoculated with 100 µg pCAGGSP7 empty vector alone (*, <i>p</i><0.05; **, <i>p</i><0.01, one-way ANOVA test).</p

JEV-infected Vero cells reacted with DNA-immunized mice sera and visualized by IFA.

<p>Mice sera were obtained three weeks after the final immunization. (A) Serum from mouse immunized with pCAG-JME+pCAGGSP7. (B) Mouse anti-JEV E glycoprotein mAb as a positive control. (C) Serum from mouse immunized with pCAG-JME+pCAG-GM. (D) Serum from mouse immunized with pCAGGSP7. The figures shown are representative of five independent experiments performed. The scale bar is 50 µm.</p

Co-inoculation of GM-CSF plasmid showed the influence on the vaccine-induced Ab responses.

<p>Sera were collected from immunized mice (n = 5) three weeks after the final vaccination. The end-point titers of anti-prM-E Abs were measured by ELISA and recorded as geometrical mean titers (GMT). Gray bars, mice co-inoculated with 50 µg pCAG-GM and 50 µg pCAG-JME (JEV), pCAG-D1ME (DENV1), pCAG-D2ME (DENV2), pCAG-HCV-C (HCV-C) or pCAG-HCV-E1 (HCV-E1); hollow bars, mice inoculated with a mixture of 50 µg pCAG-JME, pCAG-D1ME, pCAG-D2ME and 50 µg pCAGGSP7 (*, <i>p</i><0.05; **, <i>p</i><0.01, t test).</p

The suppression of Ab responses by the GM-CSF plasmid was dose-dependent.

<p>(A) Mice (n = 5) were inoculated with various dosages of pCAG-GM (10, 25 and 50 µg) or pCAGGSP7 (50 µg) without booster and the expression levels of GM-CSF in the undiluted sera were monitored by ELISA at pre-inoculation and 1, 3, 5, 7 and 9 day(s) post-inoculation. The expression levels of GM-CSF are shown as the mean concentration with a SD (<i>p</i><0.01, one-way ANOVA test). (B, C) Mice (n = 5) were immunized with pCAG-JME (50 µg) plus various doses of pCAG-GM (10, 25 and 50 µg) or pCAGGSP7 (50 µg) three times at three-week intervals. Mice treated with 100 µg pCAGGSP7 served as the control. Three weeks after the final immunization, serum samples were collected and the Ab immune response was detected by ELISA. The levels of specific anti-JEV-prME Abs are shown as GMT (*, <i>p</i><0.05; **, <i>p</i><0.01, vs. pCAG-JME 50 µg+pCAGGSP7 50 µg group, one-way ANOVA test) (B). The levels of JEV-specific serum (1∶200) IgG subclasses are shown as the OD value (C), and the solid bars represent the IgG1 subtype, the hollow bars represent the IgG2a subtype. The IgG2a/IgG1 ratios of five groups are 0.613±0.045, 0.554±0.041, 0.765±0.055, 0.734±0.057 and 0.954±0.062, in turn.</p